Key facts
- This page summarizes Michael Derby's Form 4 filing for PaxMedica, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Sep 2022, 16:06.
Michael Derby - 30 Aug 2022 Form 4 Insider Report for PaxMedica, Inc.
- Reporting relationship
- Executive Chairman, Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 30 Aug 2022
- Net transaction value
- +$498,750
- SEC form
- 4
- Accepted by SEC
- 01 Sep 2022, 16:06:42 UTC
- Prior SEC filing
- 14 Oct 2022
- Next SEC filing
- 30 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Derby
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Derby filed Form 4 for PaxMedica, Inc. on 01 Sep 2022.
Change
- Previous filing in this sequence was filed on 14 Oct 2022.
- Current net transaction value: +$498,750.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PXMD
transaction
Common Stock
Purchase
- Transaction value
- $498,750
- Shares
- +95,000
- Change %
- +1.3%
- Price
- $5.25*
- Shares after
- 7,336,745
- Date
- 30 Aug 2022
- Ownership
- TardiMed Sciences, LLC
- Footnotes
- F2, F3
PXMD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 361,000
- Date
- 30 Aug 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Includes restricted stock units that vest as described in the Company's Registration Statement on Form S-1 (File No. 333-239676).
Footnote F2
These shares were purchased from the underwriters by TardiMed Sciences, LLC ("TardiMed") in the issuer's initial public offering, which closed on August 30, 2022. See footnote 3 for the reporting person's relationship to TardiMed.
Footnote F3
The reporting person is the Managing Partner of TardiMed and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.